How much does Oxiti cost for sale in India?

Osimertinib (Tagrisso) is a new oral drug that belongs to the third generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Its main role is to target EGFR mutated non-small cell lung cancer (NSCLC), especially for tumors with EGFR T790M positive mutation.

Osimertinib (Tagressa) has now been launched in the domestic market and has also been included in the medical insurance system. Patients can easily buy it at pharmacies in domestic hospitals, and the price is about four to five thousand yuan. However, the final price and detailed policies for medical insurance reimbursement will vary by region, so it is recommended that you consult your local hospital pharmacy to obtain the most accurate information.

At present, there are no Indian generic drugs of Osimertinib (Tagressa) officially marketed abroad. The ones officially marketed are mainly versions from Laos and Bangladesh, which are more affordable and can be purchased for only a few hundred yuan. These generic drugs are highly similar in ingredients to domestic original drugs, but their prices are much lower than in the domestic market, providing patients with a more economical choice.

The development of osimertinib (Tagrisso) is based on the continuous optimization and improvement of EGFR inhibitors. Compared with first- and second-generation EGFR inhibitors, osimertinib (Tagrisso) has higher selectivity and stronger activity while reducing its toxic effects on normal cells.

In clinical trials,osimertinib (Tagrisso) has shown significant efficacy, particularly in EGFR T790MpositiveNSCLC patients. This mutation is common after use of first- and second-generation EGFR inhibitors, leading to drug resistance. Osimertinib (Tagressa) can effectively overcome this resistance and is therefore approved for use in EGFR T790M-positive NSCLC patients, including those who have developed resistance to other EGFR inhibitors.

In addition,osimertinib (Tagrisso)is also approved for the first-line treatment of patients with advanced NSCLC with EGFRsensitivity mutations. Compared with traditional EGFR inhibitors, osimertinib (Tagrisso) has the advantage of less development of drug resistance, higher efficacy and lower toxic and side effects.